470 related articles for article (PubMed ID: 19155524)
1. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer.
Tan MC; Goedegebuure PS; Belt BA; Flaherty B; Sankpal N; Gillanders WE; Eberlein TJ; Hsieh CS; Linehan DC
J Immunol; 2009 Feb; 182(3):1746-55. PubMed ID: 19155524
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
3. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3
Wang X; Lang M; Zhao T; Feng X; Zheng C; Huang C; Hao J; Dong J; Luo L; Li X; Lan C; Yu W; Yu M; Yang S; Ren H
Oncogene; 2017 May; 36(21):3048-3058. PubMed ID: 27991933
[TBL] [Abstract][Full Text] [Related]
4. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence.
Yurchenko E; Tritt M; Hay V; Shevach EM; Belkaid Y; Piccirillo CA
J Exp Med; 2006 Oct; 203(11):2451-60. PubMed ID: 17015634
[TBL] [Abstract][Full Text] [Related]
5. CCR5-dependent regulatory T cell migration mediates fungal survival and severe immunosuppression.
Moreira AP; Cavassani KA; Massafera Tristão FS; Campanelli AP; Martinez R; Rossi MA; Silva JS
J Immunol; 2008 Mar; 180(5):3049-56. PubMed ID: 18292527
[TBL] [Abstract][Full Text] [Related]
6. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.
Liyanage UK; Goedegebuure PS; Moore TT; Viehl CT; Moo-Young TA; Larson JW; Frey DM; Ehlers JP; Eberlein TJ; Linehan DC
J Immunother; 2006; 29(4):416-24. PubMed ID: 16799337
[TBL] [Abstract][Full Text] [Related]
7. Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine.
Kang SG; Piniecki RJ; Hogenesch H; Lim HW; Wiebke E; Braun SE; Matsumoto S; Kim CH
Gastroenterology; 2007 Mar; 132(3):966-81. PubMed ID: 17324406
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.
Moo-Young TA; Larson JW; Belt BA; Tan MC; Hawkins WG; Eberlein TJ; Goedegebuure PS; Linehan DC
J Immunother; 2009 Jan; 32(1):12-21. PubMed ID: 19307989
[TBL] [Abstract][Full Text] [Related]
9. CCR5 ameliorates Japanese encephalitis via dictating the equilibrium of regulatory CD4(+)Foxp3(+) T and IL-17(+)CD4(+) Th17 cells.
Kim JH; Patil AM; Choi JY; Kim SB; Uyangaa E; Hossain FM; Park SY; Lee JH; Eo SK
J Neuroinflammation; 2016 Jul; 13(1):223. PubMed ID: 27439902
[TBL] [Abstract][Full Text] [Related]
10. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3.
Gao P; Zhou XY; Yashiro-Ohtani Y; Yang YF; Sugimoto N; Ono S; Nakanishi T; Obika S; Imanishi T; Egawa T; Nagasawa T; Fujiwara H; Hamaoka T
J Leukoc Biol; 2003 Feb; 73(2):273-80. PubMed ID: 12554804
[TBL] [Abstract][Full Text] [Related]
11. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis.
Tokuyama H; Ueha S; Kurachi M; Matsushima K; Moriyasu F; Blumberg RS; Kakimi K
Int Immunol; 2005 Aug; 17(8):1023-34. PubMed ID: 16000328
[TBL] [Abstract][Full Text] [Related]
12. Chemokine receptor blockade with a synthetic nonpeptide compound attenuates cardiac allograft vasculopathy.
Bastani S; Sherman W; Schnickel GT; Hsieh GR; Bhatia R; Fishbein MC; Ardehali A
Transplantation; 2009 Oct; 88(8):995-1001. PubMed ID: 19855245
[TBL] [Abstract][Full Text] [Related]
13. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.
Ward ST; Li KK; Hepburn E; Weston CJ; Curbishley SM; Reynolds GM; Hejmadi RK; Bicknell R; Eksteen B; Ismail T; Rot A; Adams DH
Br J Cancer; 2015 Jan; 112(2):319-28. PubMed ID: 25405854
[TBL] [Abstract][Full Text] [Related]
14. IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaining CCR5-amplified Treg-suppressive mechanisms.
Shao Y; Yang WY; Saaoud F; Drummer C; Sun Y; Xu K; Lu Y; Shan H; Shevach EM; Jiang X; Wang H; Yang X
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622804
[TBL] [Abstract][Full Text] [Related]
15. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells.
Chang LY; Lin YC; Kang CW; Hsu CY; Chu YY; Huang CT; Day YJ; Chen TC; Yeh CT; Lin CY
J Immunol; 2012 Jul; 189(2):567-74. PubMed ID: 22664873
[TBL] [Abstract][Full Text] [Related]
16. CCR5 dictates the equilibrium of proinflammatory IL-17+ and regulatory Foxp3+ T cells in fungal infection.
Kroetz DN; Deepe GS
J Immunol; 2010 May; 184(9):5224-31. PubMed ID: 20335531
[TBL] [Abstract][Full Text] [Related]
17. CCR5-Dependent Homing of T Regulatory Cells to the Tumor Microenvironment Contributes to Skin Squamous Cell Carcinoma Development.
de Oliveira CE; Gasparoto TH; Pinheiro CR; Amôr NG; Nogueira MRS; Kaneno R; Garlet GP; Lara VS; Silva JS; Cavassani KA; Campanelli AP
Mol Cancer Ther; 2017 Dec; 16(12):2871-2880. PubMed ID: 28904130
[TBL] [Abstract][Full Text] [Related]
18. Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis.
Lagane B; Ballet S; Planchenault T; Balabanian K; Le Poul E; Blanpain C; Percherancier Y; Staropoli I; Vassart G; Oppermann M; Parmentier M; Bachelerie F
Mol Pharmacol; 2005 Jun; 67(6):1966-76. PubMed ID: 15761117
[TBL] [Abstract][Full Text] [Related]
19. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
20. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
